Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Exp Biol Med (Maywood)
Benefits graph
doi: 10.3389/fimmu.2024.1386607 Received 15 February 2024 Accepted 11 April 2024 Published 03 June 2024 Volume 15 - 2024 Edited by Aleksandra Piechota-Polanczyk, Jagiellonian University, Poland Reviewed by Pawel Zalewski, Nicolaus Copernicus University in Toru, Poland Shuhei Sakakibara, Jikei University of Health Care Sciences, Japan Lorenzo Lorusso, ASST Lecco, Italy Updates Copyright 2024 Arron, Marsh, Kell, Khan, Jaeger and Pretorius
It promotes glucose uptake by directly upregulating GLUT1/3, promotes glycolysis by upregulating hexokinase 2 (HK2), and promotes lipogenesis by directly interacting with SREBP